Vaskonen T, Mervaala E, Teräväinen T L, Laakso J, Karppanen H, Vapaatalo H
Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Helsinki, Finland.
Blood Press. 1998 May;7(3):184-92. doi: 10.1080/080370598437402.
The influence of isosorbide-5-mononitrate (IS-5-MN) on the cardiovascular effects of high dietary salt intake (NaCl, 6.6% of dry weight of food) and that of a potassium, magnesium and l-lysine-enriched salt alternative (Pansalt 10.5%, producing a 6.6% content of NaCl) was studied in spontaneously hypertensive rats in an 8-week experiment. Common salt produced a marked rise in blood pressure and induced cardiac and renal hypertrophy, while the salt alternative, although containing the same amount of NaCl, neither increased blood pressure nor caused any significant cardiac hypertrophy. IS-5-MN treatment at a daily dose of approximately 60-70 mg/kg (mixed with food) attenuated the rise in blood pressure induced by common salt, but did not prevent the cardiac or renal hypertrophy. IS-5-MN did not offer any additional benefit to the use of the salt alternative diet alone in treatment of high blood pressure. Mesenteric arterial responses in vitro were examined at the end of the study. IS-5-MN treatment during the moderately low-salt (NaCl 0.7%) control diet tended to decrease the contractile response to noradrenaline and increase the relaxation to acetylcholine. Common salt, but not the salt alternative, induced a 50% increase in the 24-h urinary excretion of cyclic GMP. Both salt supplements induced an 8-9-fold increase in the excretion of calcium, and about a 2-fold increase in the excretion of phosphorus. Common salt also increased the excretion of magnesium by 50%. IS-5-MN treatment had no significant effect on the excretion of the mineral elements. Our findings show that increased intake of potassium and magnesium reduces the harmful effects of common salt. Pressure-independent mechanisms are involved in salt-induced left ventricular and renal hypertrophy, since they remained unaffected despite the prevention of the salt-induced rise in blood pressure by IS-5-MN treatment.
在一项为期8周的实验中,研究了单硝酸异山梨酯(IS-5-MN)对高盐饮食(氯化钠,占食物干重的6.6%)以及富含钾、镁和L-赖氨酸的替代盐(潘盐10.5%,氯化钠含量为6.6%)对自发性高血压大鼠心血管效应的影响。普通盐使血压显著升高,并诱发心脏和肾脏肥大,而替代盐虽然含有相同量的氯化钠,但既不升高血压,也不引起任何明显的心脏肥大。每日剂量约60 - 70 mg/kg(与食物混合)的IS-5-MN治疗可减轻普通盐引起的血压升高,但不能预防心脏或肾脏肥大。IS-5-MN对单独使用替代盐饮食治疗高血压没有提供任何额外益处。在研究结束时检测了肠系膜动脉的体外反应。在适度低盐(氯化钠0.7%)对照饮食期间进行IS-5-MN治疗倾向于降低对去甲肾上腺素的收缩反应,并增加对乙酰胆碱的舒张反应。普通盐而非替代盐使环磷酸鸟苷的24小时尿排泄量增加50%。两种盐补充剂均使钙排泄增加8 - 9倍,磷排泄增加约2倍。普通盐还使镁排泄增加50%。IS-5-MN治疗对矿物质元素的排泄没有显著影响。我们的研究结果表明,增加钾和镁的摄入量可降低普通盐的有害影响。盐诱导的左心室和肾脏肥大涉及与压力无关的机制,因为尽管IS-5-MN治疗可预防盐诱导的血压升高,但它们并未受到影响。